SUMMARY Sera from 71 patients with acute liver injury have been tested for antibodies to hepatocyte membrane lipoprotein complex (LSP) using a sensitive radioimmunoassay. Two main patterns of anti-LSP response were seen. In the first, seen in patients with type A and B viral hepatitis, anti-LSP antibodies were detectable at presentation, with the highest titres two to 10 days before the peak in serum aminotransferases and, in the hepatitis B patients, when viral DNA polymerase concentrations were still high, indicating active viral replication. These findings are consistent with the anti-LSP response being consequent on an interaction between T cells and neoantigens on the liver cell surface. A similar pattern was found in halothane hepatitis where immune responses to a halothane-altered liver membrane antigen are present early in the course of the disease. In the second type of response, exemplified by cases with paracetamol-induced hepatic necrosis, anti-LSP was only occasionally detectable at presentation, although present in very low titre later in the clinical course. This may be due to the release of altered antigen at the time of hepatocellular injury. The same pattern was found in a selected group of patients with uncomplicated acute alcoholic hepatitis, suggesting that in both these groups of patients the liver damage may have been due to a direct toxic effect on liver cells.
The incidence of anti-LSP antibodies in the different disease groups was compared using the x2 test with Yates's correction for small numbers. Titres of anti-LSP were compared using the non-parametric Wilcoxon rank sum test.
Results
In patients with acute viral hepatitis, anti-LSP was found in sera examined at the time of presentation in 100% and 86% respectively of those with type A and B. In non-A, non-B infection the incidence of anti-LSP (27%) was significantly lower (p<005 vs hepatitis A and p<0.005 vs hepatitis B). There were, however, no significant differences in titre in those positive for anti-LSP in the three groups (Fig.  1) . Serial studies of the anti-LSP response in relation to changes in the pattern of viral replication and onset of liver damage in four patients with acute type B hepatitis who presented early in the source of the disease showed that the peak autoimmune response occurred before the time of maximum liver injury. The highest anti-LSP titres (ranging from 1: 200 to 1: 3000) were recorded from two to 10 days before the peak in the serum aspartate aminotransferase levels at a time when DNA polymerase levels were also at their highest (Fig. 2) indicating active viral replication. In acute type A hepatitis the first serum sample obtained always had the highest serum aspartate aminotransferase and anti-LSP levels.
In contrast, only one (6%) of the 16 patients with paracetamol-induced hepatic necrosis had detectable anti-LSP in serum at presentation, a frequency significantly lower than that found in hepatitis A and B (p<0.001). The anti-LSP titre was also low (1: 60) in the one positive case. To investigate the possibility that an anti-LSP response might occur later in the course of the liver damage, serum samples were obtained from eight patients who survived two weeks or more (Fig. 3) . The peak anti-LSP response was in the second week of illness at a time when serum aminotransferases were falling, the antibody being detected in four out of five cases studied at this time.
The titres were low (1:50 to 1: 60) in all those patients and were significantly lower than those found in patients with acute viral hepatitis (p<0.01).
The findings in patients with acute alcoholic hepatitis were similar to those with paracetamolinduced liver damage, only one (11%) having detectable anti-LSP antibodies in low titre in serum (Fig. 1) . The frequency was higher in those with halothane-associated hepatitis (five (63%) of the eight cases studied), but the titre of anti-LSP was, with one exception, low (<1:50). relation to the course of the illness. 
The finding of an anti-LSP response in halothane hepatitis, although titres were lower than in viral hepatitis, is in accord with the recent studies which have suggested that the immunopathology in these patients may be very similar to that in virus infection. Most patients with halothane-associated fulminant hepatic failure have antibodies in the serum which react with a neoantigen on the surface of hepatocytes isolated from halothaneanaesthetised rabbits. 14 Formation of this neoantigen is associated with the metabolic degradation of halothane via an oxidative pathway. 15 This could be the stimulus for a T-cell response which, through a helper effect, could also activate anti-LSP antibody formation. Direct lymphocyte cytotoxicity studies have confirmed such a dual response in these patients directed aainst both halothane-altered and LSP determinants.
A quite different pattern of response was observed in the patients with paracetamol-induced hepatic necrosis, anti-LSP being rarely detectable at presentation and found only in low titre later in the course of the illness. The liver damage after paracetamol overdose is due to the production of reactive metabolites of the drug which bind to microsomal ?roteins and disrupt normal cellular metabolism.1 Using techniques similar to those developed to detect the halothane-altered liver membrane determinants described above we have been unable to demonstrate immune responses to paracetamol-altered liver cells.14 In the absence of membrane alterations, T helper cells would not be activated and early loss of tolerance would not occur. Altered liver antigens, however, might be released at the time of hepatocyte necrosis and it is possible that these were responsible for the later, low-titre anti-LSP response that was observed.
The findings in acute alcoholic hepatitis were similar to those in patients with paracetamolinduced liver damage and suggest that alcohol or a metabolite was acting as a direct chemical hepatotoxin. However, these cases were all selected as examples of an uncomplicated acute hepatitic reaction and, in a larger series of patients with various types of alcohol-related liver damage, anti-LSP antibodies have been detected in several cases with cirrhosis and the histological features of portal lymphocytic infiltration and periportal hepatocyte necrosis similar to that seen in chronic active hepatitis.'8 It is possible that the wide variation in the histological response to alcohol reflects the balance between direct alcohol toxicity on the one hand and immune responses induced by alcoholaltered liver antigens on the other.
It is not clear whether the autoimmune response to LSP described here in some patients with acute hepatitis contributes to liver damage in vivo, although it is clear that it does not always follow liver injury. Liver biopsy was not indicated in the majority of patients and a comparison of the histological pattern of liver damage between those with and those without anti-LSP is therefore not possible. The anti-LSP antibodies detected by the radioimmunoassay used here are almost certainly unrelated to 'liver membrane antibodies' described in some cases of acute and chronic active hepatitis19 and detected by immonufluorescence as antibodies that will bind to isolated rabbit hepatocytes. The antigenic determinants with which the majority of this liver membrane antibody reacts (LMAg) are not found in the t1pe of LSP preparation used in the present study. 0 disease. 
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